Efficacy and risk of cytotoxic chemotherapy in extensive disease-small cell lung cancer patients with interstitial pneumonia

Table 4 Characteristics of patients with ED-SCLC and IP (n = 31)

	D-ILD (+)	D-ILD (−)	P*
	n = 7	n = 24	P*
Age, median (range), years, n (%)	70 (62–76)	74 (47–82)
< 75 years	1 (14.3)	15 (62.5)	0.25
≥75 years	6 (85.7)	9 (37.5)	0.25
Gender, n (%)
Male	6 (85.7)	22 (91.7)	0.64
Female	1 (14.3)	2 (8.3)	0.64
Smoking status, n (%)
Never	1 (14.3)	1 (4.2)	0.36
Former/Current	6 (85.7)	22 (91.7)	0.36
ECOG PS, n (%)
0/1	1 (14.3)	18 (75)	0.004
2/3/4	6 (85.7)	6 (25)	0.004
Blood testss, mean ± SD
Alb, g/dL	3.2 ± 0.5	3.7 ± 0.4	0.03
LDH, IU/L	651.7 ± 482.0	301.4 ± 110.7	0.01
CRP, mg/dL	8.9 ± 9.6	1.8 ± 1.8	0.008
KL-6, U/mL	1104.0 ± 555.1	823.8 ± 821.0	0.09
SP-D, U/mL	221.7 ± 118.7	120.5 ± 78.1	0.11
Regimen of initial chemotherapy, n (%)
CDDP + ETP	0 (0)	5 (20.8)	0.005*
CBDCA + ETP	4 (57.1)	18 (75)
AMR	3 (42.9)	1 (4.2)

* p-values were analyzed by the χ² test
Note: D-ILD drug-induced interstitial lung disease, PS performance status, SD standard deviation, Alb albumin, LDH lactate dehydrogenase, CRP C-reactive protein, KL-6 Krebs von den Lungen-6, SP-D pulmonary surfactant protein-D, CDDP cisplatin, CBDCA carboplatin, ETP etoposide, AMR amrubicin

ISSN: 1471-2407